1-2 of 2
J Rosenstock
Close
Save search
Follow your search
Access your saved searches in your account
Would you like to receive an alert when new items match your search?
Close Modal
Sort by
Journal Articles

Canagliflozin compared with sitagliptin for patients with type 2 diabetes who do not have adequate glycemic control with metformin plus sulfonylurea: a 52-week randomized trial. Diabetes Care 2013;36:2508–2515

G Schernthaner, JL Gross, J Rosenstock, M Guarisco, M Fu, J Yee, M Kawaguchi, W Canovatchel, G Meininger
Journal: Diabetes Care
Diabetes Care 2013;36(12):4172
https://doi.org/10.2337/dc13-er12a
Published: 13 November 2013
View article titled, Canagliflozin compared with sitagliptin for patients with type 2 diabetes who do not have adequate glycemic control with metformin plus sulfonylurea: a 52-week randomized trial. Diabetes Care 2013;36:2508–2515
Open the PDF for Canagliflozin compared with sitagliptin for patients with type 2 diabetes who do not have adequate glycemic control with metformin plus sulfonylurea: a 52-week randomized trial. Diabetes Care 2013;36:2508–2515 in another window
Meeting Abstracts

Basal insulin glargine (HOE 901) versus NPH insulin in patients with type 1 diabetes on multiple daily insulin regimens. U.S. Insulin Glargine (HOE 901) Type 1 Diabetes Investigator Group.

J Rosenstock, G Park, J Zimmerman, U.S. Insulin Glargine (HOE 901) Type 1 Diabetes Investigator Group
Journal: Diabetes Care
Diabetes Care 2000;23(8):1137–1142
https://doi.org/10.2337/diacare.23.8.1137
Published: 01 August 2000
View article titled, Basal insulin glargine (HOE 901) versus NPH insulin in patients with type 1 diabetes on multiple daily insulin regimens. U.S. Insulin Glargine (HOE 901) Type 1 Diabetes Investigator Group.
Open the PDF for Basal insulin glargine (HOE 901) versus NPH insulin in patients with type 1 diabetes on multiple daily insulin regimens. U.S. Insulin Glargine (HOE 901) Type 1 Diabetes Investigator Group. in another window